Emerging role of the gut microbiome in post-infectious irritable bowel syndrome: A literature review

Post-infectious irritable bowel syndrome (PI-IBS) is a particular type of IBS, with symptom onset after an acute episode of infectious gastroenteritis. Despite infectious disease resolution and clearance of the inciting pathogen agent, 10% of patients will develop PI-IBS. In susceptible individuals,...

Full description

Saved in:
Bibliographic Details
Published in:World journal of gastroenterology : WJG 2023-06, Vol.29 (21), p.3241-3256
Main Authors: Lupu, Vasile Valeriu, Ghiciuc, Cristina Mihaela, Stefanescu, Gabriela, Mihai, Cristina Maria, Popp, Alina, Sasaran, Maria Oana, Bozomitu, Laura, Starcea, Iuliana Magdalena, Adam Raileanu, Anca, Lupu, Ancuta
Format: Article
Language:English
Subjects:
Animals
Communicable Diseases
Gastroenteritis - complications
Gastrointestinal Microbiome
Irritable Bowel Syndrome - diagnosis
Post-Infectious Disorders
Review
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Post-infectious irritable bowel syndrome (PI-IBS) is a particular type of IBS, with symptom onset after an acute episode of infectious gastroenteritis. Despite infectious disease resolution and clearance of the inciting pathogen agent, 10% of patients will develop PI-IBS. In susceptible individuals, the exposure to pathogenic organisms leads to a marked shift in the gut microbiota with prolonged changes in host-microbiota interactions. These changes can affect the gut-brain axis and the visceral sensitivity, disrupting the intestinal barrier, altering neuromuscular function, triggering persistent low inflammation, and sustaining the onset of IBS symptoms. There is no specific treatment strategy for PI-IBS. Different drug classes can be used to treat PI-IBS similar to patients with IBS in general, guided by their clinical symptoms. This review summarizes the current evidence for microbial dysbiosis in PI-IBS and analyzes the available data regarding the role of the microbiome in mediating the central and peripheral dysfunctions that lead to IBS symptoms. It also discusses the current state of evidence on therapies targeting the microbiome in the management of PI-IBS. The results of microbial modulation strategies used in relieving IBS symptomatology are encouraging. Several studies on PI-IBS animal models reported promising results. However, published data that describe the efficacy and safety of microbial targeted therapy in PI-IBS patients are scarce. Future research is required.
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v29.i21.3241